Evidence map›Paper›PMID 38740826›Full record

ArticleScientific reports2024

Dynamic changes in extracellular vesicle-associated miRNAs elicited by ultrasound in inflammatory bowel disease patients.

Florian Tran, Alena Scharmacher, Nathan Baran, Neha Mishra, Marek Wozny, Samuel Pineda Chavez, Archana Bhardwaj, Sophia Hinz, Simonas Juzenas, Joana P Bernardes and 10 more

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Florian TranInstitute of Clinical Molecular Biology, University Medical Center Schleswig-Holstein, Christian Albrecht University Kiel, Campus Kiel, Rosalind-Franklin-Strasse 12, 24105, Kiel, Germany. f.tran@ikmb.uni-kiel.de.
Alena Scharmacher *Institute of Clinical Molecular Biology, University Medical Center Schleswig-Holstein, Christian Albrecht University Kiel, Campus Kiel, Rosalind-Franklin-Strasse 12, 24105, Kiel, Germany.
Nathan Baran *Institute of Clinical Molecular Biology, University Medical Center Schleswig-Holstein, Christian Albrecht University Kiel, Campus Kiel, Rosalind-Franklin-Strasse 12, 24105, Kiel, Germany.
Neha MishraInstitute of Clinical Molecular Biology, University Medical Center Schleswig-Holstein, Christian Albrecht University Kiel, Campus Kiel, Rosalind-Franklin-Strasse 12, 24105, Kiel, Germany.
Marek WoznyDepartment of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Italy.
Samuel Pineda ChavezDepartment of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Italy.
Archana BhardwajInstitute of Clinical Molecular Biology, University Medical Center Schleswig-Holstein, Christian Albrecht University Kiel, Campus Kiel, Rosalind-Franklin-Strasse 12, 24105, Kiel, Germany.
Sophia HinzInstitute of Clinical Molecular Biology, University Medical Center Schleswig-Holstein, Christian Albrecht University Kiel, Campus Kiel, Rosalind-Franklin-Strasse 12, 24105, Kiel, Germany.
Simonas JuzenasInstitute of Clinical Molecular Biology, University Medical Center Schleswig-Holstein, Christian Albrecht University Kiel, Campus Kiel, Rosalind-Franklin-Strasse 12, 24105, Kiel, Germany.
Joana P BernardesInstitute of Clinical Molecular Biology, University Medical Center Schleswig-Holstein, Christian Albrecht University Kiel, Campus Kiel, Rosalind-Franklin-Strasse 12, 24105, Kiel, Germany.
Laura Katharina SieversInstitute of Clinical Molecular Biology, University Medical Center Schleswig-Holstein, Christian Albrecht University Kiel, Campus Kiel, Rosalind-Franklin-Strasse 12, 24105, Kiel, Germany.
Matthias LessingDepartment of Internal Medicine I, University Medical Center Schleswig-Holstein, 24105, Kiel, Germany.
Konrad AdenInstitute of Clinical Molecular Biology, University Medical Center Schleswig-Holstein, Christian Albrecht University Kiel, Campus Kiel, Rosalind-Franklin-Strasse 12, 24105, Kiel, Germany.
Arne LassenDepartment of Internal Medicine I, University Medical Center Schleswig-Holstein, 24105, Kiel, Germany.
Arne BergfeldDepartment of Internal Medicine I, University Medical Center Schleswig-Holstein, 24105, Kiel, Germany.
Hauke Jann WeberDepartment of Gastroenterology, Asklepios Westklinikum, 22559, Hamburg, Germany.
Lennart NeasDepartment of Internal Medicine III, University Medical Center Schleswig-Holstein, 24105, Kiel, Germany.
Stefania VetranoDepartment of Biomedical Sciences, Humanitas University, 20072, Pieve Emanuele, Italy.
Stefan SchreiberInstitute of Clinical Molecular Biology, University Medical Center Schleswig-Holstein, Christian Albrecht University Kiel, Campus Kiel, Rosalind-Franklin-Strasse 12, 24105, Kiel, Germany.
Philip RosenstielInstitute of Clinical Molecular Biology, University Medical Center Schleswig-Holstein, Christian Albrecht University Kiel, Campus Kiel, Rosalind-Franklin-Strasse 12, 24105, Kiel, Germany.

Funding

Bundesministerium für Bildung und Forschung 01ZX1902ADeutsche Forschungsgemeinschaft 390884018Innovative Medicines Initiative 853995
6 · The paper itself

Abstract

Blood-based biomarkers that reliably indicate disease activity in the intestinal tract are an important unmet need in the management of patients with IBD. Extracellular vesicles (EVs) are cell-derived membranous microparticles, which reflect the cellular and functional state of their site of site of origin. As ultrasound waves may lead to molecular shifts of EV contents, we hypothesized that application of ultrasound waves on inflamed intestinal tissue in IBD may amplify the inflammation-specific molecular shifts in EVs like altered EV-miRNA expression, which in turn can be detected in the peripheral blood. 26 patients with IBD were included in the prospective clinical study. Serum samples were collected before and 30 min after diagnostic transabdominal ultrasound. Differential miRNA expression was analyzed by sequencing. Candidate inducible EV-miRNAs were functionally assessed in vitro by transfection of miRNA mimics and qPCR of predicted target genes. Serum EV-miRNA concentration at baseline correlated with disease severity, as determined by clinical activity scores and sonographic findings. Three miRNAs (miR-942-5p, mir-5588, mir-3195) were significantly induced by sonography. Among the significantly regulated EV-miRNAs, miR-942-5p was strongly induced in higher grade intestinal inflammation and correlated with clinical activity in Crohn's disease. Prediction of target regulation and transfection of miRNA mimics inferred a role of this EV-miRNA in regulating barrier function in inflammation. Induction of mir-5588 and mir-3195 did not correlate with inflammation grade. This proof-of-concept trial highlights the principle of induced molecular shifts in EVs from inflamed tissue through transabdominal ultrasound. These inducible EVs and their molecular cargo like miRNA could become novel biomarkers for intestinal inflammation in IBD.

Indexed as

Extracellular VesiclesInflammatory Bowel DiseasesMicroRNAsUltrasonographyAdultBiomarkersFemaleHumansMaleMiddle AgedProspective StudiesBiomarkersMicroRNAsBiomarker discoveryExtracellular vesiclesInflammatory bowel diseaseLiquid biopsiesSonography

Identifiers

PMID38740826
PMCPMC11091140

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.